Previous 10 |
Cobomarsen tested in clinical trials for three different types of blood cancers Multiple clinical sites open and actively recruiting in the global Phase 2 SOLAR clinical trial of cobomarsen in CTCL Data from four clinical trials of three product candidates expected to be released i...
BOULDER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer...
BOULDER, Colo., Feb. 20, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, March 13, at 4:30 p.m. ET to discuss its fina...
Gainers: Organogenesis Holdings ( ORGO ) +57% . Rand Capital (NASDAQ: RAND ) +32% . PHI (NASDAQ: PHII ) +26% . ClearOne (NASDAQ: CLRO ) +23% . Bristow Group (NYSE: BRS ) +20% . Digital Ally (NASDAQ: DGLY ) +17% . SITO Mobile (NASDAQ: SITO ) +16% . Achaogen (NASDAQ: AKAO ) +16% . C...
The following slide deck was published by Miragen Therapeutics, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...